Home | Clinical Care | Research | Training | Division Activities

Education and Training:

B.A., Chemistry, Northwestern University (1975)

M.D., Vanderbilt University (1979)

Residency in Medicine, Rush Presbyterian-St. Lukes, Chicago, IL (1980-82)

Fellowship in Hematology/Oncology, University of Michigan, Ann Arbor, MI (1984-88)

Research Associate, Howard Hughes Medical Institute, Ann Arbor, MI (1985-88)

Barbara A. Konkle, M.D.
Professor of Medicine
University of Washington School of Medicine

Director, Clinical and Translational Research
Medical Director, Hemostasis Reference Laboratory
Puget Sound Blood Center

Photo Dr. Barbara Konkle


Office Address:
Puget Sound Blood Center
Box 359190
921 Terry Avenue
Seattle, WA 98104
Phone:   (206) 689-6191
Fax:       (866) 291-0025
E-mail:   BarbaraK@psbc.org

CURRENT CLINICAL INTERESTS

Disorders of hemostasis and thrombosis


CURRENT RESEARCH INTERESTS

Clinical and translational research in hemostasis, thrombosis, transfusion medicine, and sickle cell disease


RESEARCH DESCRIPTION

Clinical Studies/Trials in Hemostasis, Thrombosis and Sickle Cell Disease:
Dr. Konkle has several active federally-funded studies focusing on the clinical impact of hemostasis and thrombosis. These include 1) A feasibility study of low molecular weight heparin to prevent postpartum thrombosis in women at higher risk for venous thromboembolism (NHLBI R34), 2) A study to determine biomarkers predictive of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization and cardiopulmonary bypass surgery (NIH RC1), 3) A cross sectional analysis of cardiovascular disease and complications of anticoagulant and antithrombotic therapy in men with moderate and severe hemophilia (CDC), and 4) A study of N-acetylcysteine in patients with sickle cell disease to evaluate safety and laboratory endpoints of hemolysis and changes in von Willebrand factor NHLBI RO1).

She has a long standing interest in laboratory assessment of bleeding and thrombotic disorders and in the development of new testing. She is co-leading a nationwide project to provide mutation analysis to patients with hemophilia, to assess next generation sequencing in this context, and to provide a repository for future research. She is evaluating laboratory assays for von Willebrand disease and hemophilia with aims to develop testing with improved correlation with bleeding phenotype, and to predict thrombotic risk postpartum.

She is involved in clinical trials of new therapies for hemophilia and von Willebrand disease, and studies of outcomes in hemophilia (HUGS).


REPRESENTATIVE PUBLICATIONS

Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of rFVIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 5:1904-1913, 2007.

Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 15:1197-1209, 2009.

Metjian A, Wang C, Sood S, Cuker A, Peterson S, Soucie J, Konkle BA. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia. 15:918-925, 2009.

Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB. The HIT expert probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 8:2642-2650, 2010.

Soucie JM, Wang C, Siddiqi A, Kulkarni R, Recht M,  Konkle BA and The Hemophilia Treatment Center Network. The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia. 17:196-203, 2011.

Sood SL, Cuker A, Wang C, Metjian AD, Chiang EY, Soucie JM, Konkle BA and the HTCN Study Investigators. Similarity in joint function limitation in type 3 von Willebrand disease and moderate Hemophilia A. Haemophilia. 2013;19:595-601.

Chen J, Chung DW, Le J, Liang M, Konkle BA, Lopez JA. Normal cleavage of von Willebrand factor by ADAMTS13 in the absence of factor VIII in patients with severe Hemophilia A. J Thromb. Haemost. 2013;11:1769-1772.

Cuker A, Rauova L, Bolgiano D, Matthai WH, Poncz M, Konkle BA. Atherosclerosis is not a risk factor for anti-platelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery. Thromb. Haemost. 2014;111:1191-1193. PMCID: PMC4043923

James AH, Konkle BA, Kouides P, Ragni MV, Thames B, Gupta S, Sood S, Philipp CS. Post-partum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Accepted for publication in Haemophilia.

Rodger M, Wilson MI, Phillips P, Kahn S, James A, Konkle BA. Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot randomized placebo control trial. Accepted for publication in Thrombosis and Haemostasis.